ReviewMicrosystems & nanoengineering2026
Engineering etiology-aligned in vitro models of human vessels.
Review in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Vascular diseases remain a major global health burden, yet traditional animal models often fail to capture the human-specific mechanisms that drive disease progression. Recent policy shifts, including the FDA Modernization Act and the NIH's transition away from animal-only studies, have intensified the need for human-relevant vascular platforms. This review introduces an etiology-to-model framework that maps six principal classes of vascular disease, including congenital, metabolic, neoplastic, inflammatory, degenerative, and risk factor-induced, to the in vitro systems best equipped to reproduce their defining microenvironmental disturbances. We evaluate how 2D assays, organoids, organ-on-chip platforms, tissue-engineered grafts, and bioprinted vessels each recapitulate distinct structural, cellular, and hemodynamic features of human pathology. We argue that the central challenge is no longer the lack of advanced tools, but the need to validate models against disease-specific benchmarks and integrate biological complexity without compromising reproducibility. By embedding disease etiology into model design, this framework provides a foundation for developing predictive vascular platforms that accelerate mechanistic insight and support precision therapy development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.